PubMed · 1999 · 25 citations · 0 references
MedicineHematologySurgeryHemodynamic ManagementHemostasisVascular SurgeryDeep Vein ThrombosisThromboembolic DiseaseThromboembolic OutcomesThrombosisThrombotic DisordersVenous ThromboembolismDeep Vein Thrombosis EvaluationDeep Vein Thrombosis ManagementDeep Vein Thrombosis TreatmentDeep Venous InsufficiencyDistal Deep Vein ThrombosisRecurrent Deep Vein ThrombosisVenous Thromboembolism AssessmentVenous Thromboembolism Epidemiology
No prospective study of the long-term sequelae of more than 10 years after acute deep vein thrombosis exists so far. Therefore, 28 patients with DVT were included in a prospective study to evaluate the natural history of postthrombotic syndrome. Clinical and hemodynamic examinations were performed at the time of admission; after 3, 6 and 12 months; after the 2nd, 3rd, 4th, 5th; and finally after the 12th year. All patients received unfractionated heparin initially and oral anticoagulants subsequently. After 12 years, 64% of the patients exhibited normal findings. Mild skin changes were found in 28%, marked trophic changes in 5%, and only 1 venous ulcer occurred. Regular use of compression stockings was reported by 54% of the patients with multilevel disease. Although mean maximum venous outflow was significantly reduced from the acute event to 2 years later (p < 0.003) compared with the contralateral leg, a significant (p < 0.05) improvement was observed 6 months later. Recanalization of calf vein thrombosis was detected by Doppler sonography after 3 months. 64% of the multilevel thromboses were recanalized completely or in part after 1 year; in 69%, valvular incompetence was found. In conclusion, in contrast to earlier reports, this prospective study up to 12 years after DVT demonstrates a low incidence of PTS by administration of initially unfractionated heparin, oral anticoagulation and compression therapy. However, the adverse clinical event rate (mortality 14%) and recurrency rate of 24% show that the prognosis after DVT does not appear favorable even in low-risk patients.